TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

TCL.AU

13.59

+1.12%↑

BXB.AU

20.59

+1.73%↑

COL.AU

19.82

-0.45%↓

QAN.AU

8.81

-2.33%↓

CAR.AU

33.14

+2.51%↑

Search

CSL Ltd

Uždarymo kaina

SektoriusPramonės sektorius

255.36 1.89

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

250.4

Max

256

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.3B

2B

Pardavimai

1.5B

8.2B

P/E

Sektoriaus vid.

28.972

35.58

Pelnas, tenkantis vienai akcijai

1.831

Dividendų pajamingumas

1.7

Pelno marža

24.437

Darbuotojai

32,698

EBITDA

1.5B

3.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+27.2% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.70%

2.64%

Kitas dividendų mokėjimo data

2025-04-09

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-14B

121B

Ankstesnė atidarymo kaina

253.47

Ankstesnė uždarymo kaina

255.36

Naujienos nuotaikos

By Acuity

50%

50%

207 / 468 reitingas Industrials

CSL Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-10 21:55; UTC

Uždarbis

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025-02-10 21:34; UTC

Uždarbis

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

2024-08-12 23:23; UTC

Uždarbis

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

2024-08-12 22:49; UTC

Uždarbis

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

2025-03-21 02:03; UTC

Rinkos pokalbiai

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

2025-02-11 22:30; UTC

Rinkos pokalbiai

Flu Vaccines Proving Problematic for CSL -- Market Talk

2025-02-10 21:40; UTC

Uždarbis

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025-02-10 21:19; UTC

Uždarbis

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

2025-02-10 21:13; UTC

Uždarbis

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

2025-02-10 21:12; UTC

Uždarbis

CSL Interim Dividend US$1.30/Security

2025-02-10 21:12; UTC

Uždarbis

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

2025-02-10 21:11; UTC

Uždarbis

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

2024-11-07 03:53; UTC

Rinkos pokalbiai

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

2024-10-22 22:53; UTC

Rinkos pokalbiai

CSL's R&D Update Seen as Neutral Overall -- Market Talk

2024-10-10 22:20; UTC

Rinkos pokalbiai

CSL Bull Looking for Update on Gross Margin -- Market Talk

2024-08-13 00:33; UTC

Rinkos pokalbiai

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

2024-08-12 22:34; UTC

Uždarbis

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

2024-08-12 22:18; UTC

Uždarbis

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

2024-08-12 22:18; UTC

Uždarbis

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

2024-08-12 22:17; UTC

Uždarbis

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

2024-08-12 22:16; UTC

Uždarbis

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

2024-08-12 22:15; UTC

Uždarbis

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

2024-08-12 22:14; UTC

Uždarbis

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

2024-08-12 22:13; UTC

Uždarbis

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

2024-08-12 22:13; UTC

Uždarbis

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

2024-08-12 22:11; UTC

Uždarbis

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

2024-08-12 22:10; UTC

Uždarbis

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

2024-08-12 22:09; UTC

Uždarbis

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

2024-08-12 22:08; UTC

Uždarbis

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

2024-08-12 22:07; UTC

Uždarbis

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Akcijų palyginimas

Kainos pokytis

CSL Ltd Prognozė

Kainos tikslas

By TipRanks

27.2% į viršų

12 mėnesių prognozė

Vidutinis 317.093 AUD  27.2%

Aukščiausias 360.3 AUD

Žemiausias 250 AUD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CSL Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

12

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

207 / 468 reitingas Pramonės sektorius

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.